سعر رونتيجرون 400مجم 20 قرص 2023

Dexibuprofen 400 mg scored film-coated tablets; a non-steroidal anti-inflammatory drug (propionic acid derivative) used as an analgesic and anti-inflammatory.

• Pain and inflammation in osteoarthritis/arthrosisPopulation: Adults and children/adolescents from 8 yearsUK eMC (medicines.org.uk) / MHRA
• Primary dysmenorrhoea (menstrual pain)Population: Adults and children/adolescents from 8 yearsUK eMC (medicines.org.uk) / MHRA
• Mild to moderate pain such as musculoskeletal pain, headache or toothache, painful swelling and inflammation after injuryPopulation: Adults and children/adolescents from 8 yearsUK eMC (medicines.org.uk) / MHRA

• Very common: dyspepsia, abdominal pain. Common: diarrhoea, nausea, vomiting, rash, drowsiness, headache, dizziness, vertigo, fatigue.International label, same formulation · UK eMC (medicines.org.uk) / MHRA
• Uncommon: GI ulcers and bleeding, gastritis, urticaria, pruritus, angioedema, visual disturbances, tinnitus, insomnia, anxiety, rhinitis, bronchospasm.International label, same formulation · UK eMC (medicines.org.uk) / MHRA
• Rare/very rare: GI perforation, blood disorders, anaphylaxis, hepatitis/jaundice, severe skin reactions, interstitial nephritis, acute renal failure, aseptic meningitis.International label, same formulation · UK eMC (medicines.org.uk) / MHRA

• Hypersensitivity to dexibuprofen, any other NSAID or any excipient.International label, same formulation · UK eMC (medicines.org.uk) / MHRA
• Patients in whom aspirin or other NSAIDs precipitate asthma, bronchospasm, acute rhinitis, nasal polyps, urticaria or angioneurotic oedema.International label, same formulation · UK eMC (medicines.org.uk) / MHRA
• History of GI bleeding or perforation related to previous NSAID therapy; active or history of recurrent peptic ulcer/haemorrhage.International label, same formulation · UK eMC (medicines.org.uk) / MHRA

• Gastrointestinal bleeding, ulceration and perforation, which can be fatal, may occur at any time; risk is higher with higher doses, history of ulcer, alcoholism and in the elderly. Consider gastroprotection in at-risk patients.International label, same formulation · UK eMC (medicines.org.uk) / MHRA
• Cardiovascular: high doses (1200 mg/day) may carry an arterial thrombotic risk similar to high-dose ibuprofen; use only after careful consideration in uncontrolled hypertension, heart failure, ischaemic heart disease, peripheral arterial or cerebrovascular disease.International label, same formulation · UK eMC (medicines.org.uk) / MHRA
• Caution in bronchial asthma, allergic rhinitis, nasal polyps or COPD because of possible bronchospasm; stop at the first sign of hypersensitivity.International label, same formulation · UK eMC (medicines.org.uk) / MHRA

• Anticoagulants (e.g. warfarin)NSAIDs may enhance the anticoagulant effect; concomitant use not recommended; check INR/bleeding time and adjust dose.UK eMC (medicines.org.uk) / MHRA
• MethotrexateNSAIDs may increase methotrexate levels and toxicity; not recommended with doses of 15 mg/week or more; monitor blood counts with lower doses.UK eMC (medicines.org.uk) / MHRA
• LithiumNSAIDs can increase lithium plasma levels; combination not recommended, monitor lithium if necessary.UK eMC (medicines.org.uk) / MHRA

• Prostaglandin synthesis inhibition may adversely affect pregnancy and embryo-fetal development; contraindicated in the third trimester.International label, same formulation · UK eMC (medicines.org.uk) / MHRA
• Ibuprofen is slightly excreted in milk; breastfeeding is possible with low doses for short periods; consider early weaning with longer use or higher doses.International label, same formulation · UK eMC (medicines.org.uk) / MHRA

• Dexibuprofen: Pharmacologically active S(+)-enantiomer of ibuprofen; non-selective inhibition of prostaglandin synthesis gives analgesic, anti-inflammatory and antipyretic effects and inhibits platelet aggregation.